Immuron (IMRN) Return on Capital Employed (2018 - 2024)
Immuron's quarterly Return on Capital Employed came in at 56732272386237.33% in Q4 2024, up 5673227256904359.0% year-on-year from N/an in Q1 2024, and up 31034097593.38% quarter-over-quarter from 182806.26% in Q4 2023.
Immuron has reported Return on Capital Employed for 7 years, with the latest figure at 56732272386237.33% in Q4 2024.
- For the quarter ending Q4 2024, Return on Capital Employed rose 5673227256904359.0% year-over-year to 56732272386237.33%; the trailing twelve-month figure through Dec 2024 stood at 56732272386237.33% (up 5673227256904359.0% YoY), and the FY2025 full-year result was 166.05%, down 13738.0% from the prior year.
- Return on Capital Employed for Q4 2024 stood at 56732272386237.33%, up from 182806.26% in the prior quarter.
- The five-year high for Return on Capital Employed was 56732272386237.33% in Q4 2024, with the low at 182806.26% in Q4 2023.
- Average Return on Capital Employed over 5 years is 9455378656724.83%, with a median of 84277.31% recorded in 2021.
- Year-over-year, Return on Capital Employed slumped 9897611 bps in 2023 and soared 2000000000 bps in 2024.
- Tracing IMRN's Return on Capital Employed over 5 years: stood at 8.56% in 2020, then sank by 989453 bps to 84724.47% in 2021, then increased by 1 bps to 83830.15% in 2022, then sank by 118 bps to 182806.26% in 2023, then jumped by 2000000000 bps to 56732272386237.33% in 2024.
- The last three Return on Capital Employed figures came in at 56732272386237.33% (Q4 2024), 182806.26% (Q4 2023), and 94536.06% (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 56,732,272,386,237.33% |
| Dec 31, 2023 | -182,806.26% |
| Jun 30, 2023 | -94,536.06% |
| Dec 31, 2022 | -83,830.15% |
| Dec 31, 2021 | -84,724.47% |
| Dec 31, 2020 | 8.56% |
| Dec 31, 2019 | 158.52% |
| Dec 31, 2018 | 49.53% |